Loading...

Race Oncology Limited

RAC.AXASX
Healthcare
Biotechnology
$2.50
$-0.11(-4.21%)
Australian Market is Open • 13:36

Race Oncology Limited (RAC.AX) Stock Competitors & Peer Comparison

See (RAC.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
RAC.AXA$2.76+8.66%516.4M-55.20-A$0.05N/A
CSL.AXA$97.96+0.72%46.9B11.50A$8.52+4.35%
TLX.AXA$14.72-0.88%5B-490.67-A$0.03N/A
MSB.AXA$2.11+2.93%2.7B-21.10-A$0.10N/A
NEU.AXA$12.79-0.47%1.6B55.61A$0.23N/A
CU6.AXA$2.90+0.69%1.1B-10.36-A$0.28N/A
PYC.AXA$1.43-1.04%833.8M-17.87-A$0.08N/A
OPT.AXA$0.60+0.00%820.8M-1.40-A$0.43N/A
CUV.AXA$9.47-0.73%477.4M14.80A$0.64+0.53%
SPL.AXA$0.62-6.06%261M-62.00-A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

RAC.AX vs CSL.AX Comparison May 2026

RAC.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAC.AX stands at 516.4M. In comparison, CSL.AX has a market cap of 46.9B. Regarding current trading prices, RAC.AX is priced at A$2.76, while CSL.AX trades at A$97.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAC.AX currently has a P/E ratio of -55.20, whereas CSL.AX's P/E ratio is 11.50. In terms of profitability, RAC.AX's ROE is -0.47%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, RAC.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for RAC.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions